

# NH VaxWell Vaccination Updates

June 9<sup>th</sup>, 2023

Ryan Tannian

Bureau of Infectious Disease Control



NH DIVISION OF  
Public Health Services  
Department of Health and Human Services



# Agenda

- ▶ End of PHE
- ▶ Dashboards
- ▶ COVID-19 Vaccination
- ▶ Mpox Vaccination
- ▶ RSV Vaccination
- ▶ Other Vaccine Updates

# End of the Federal Public Health Emergency (PHE)

# End of PHE

## ▶ **May 11<sup>th</sup>, 2023 – End of Federal PHE**

[Fact Sheet: End of the COVID-19 Public Health Emergency](#)

- ## ▶ **May 31<sup>st</sup>, 2023 - NH Mobile Vaccine services ended**
- Access to COVID-19 vaccines generally not impacted at this time
  - COVID-19 vaccine will remain available at no-cost until the current federal supply is exhausted or as outlined in other programs and initiatives from the U.S. Department of Health & Human Services

# HHS Bridge Access Program for COVID-19 Vaccines and Treatments

## ▶ **Two components**

- Support existing public sector vaccine safety net through local health departments and HRSA supported health centers
- Create a new partnership with pharmacy chains to offer COVID-19 vaccine and treatments to uninsured free of charge

## ▶ **Commercialization transition plan**

- Projected to be funded through December, 2024

## ▶ **More to come on what the HHS Bridge Access Program will look like in NH**

# COVID-19 Vaccine

# COVID-19 Vaccine

- ▶ **Anticipate a new formulation for Fall 2023**
  - WHO Technical Advisory Group (TAG)
    - Recommending monovalent formulation, removing the index virus
    - XBB.1 descendent lineages are the predominate circulating strains globally
    - Will U.S. take this approach?
  
- ▶ **CDC Fall campaign**
  - Limited details
  
- ▶ **New Hampshire**
  - Fall media and education campaign
  - Both mass media/general public and focused messaging to certain populations

# Dashboard Updates



# Updated Dashboards and Website

- ▶ **Streamlined dashboards**

- [www.nh.gov/covid19](http://www.nh.gov/covid19)

- ▶ **Reflect updated reporting requirements**

- ▶ **Vaccine dashboard has transitioned to the Data Portal**

- WISDOM

[NH DHHS Data Portal](#)

- ▶ **Historical data remains available**

# Mpox Vaccination Updates

# Mpox Vaccine Updates

- ▶ **Multiple campaigns aligned with Pride month and summer festivals/activities**
  - CDC – [Get Healthy and Ready for Summer 2023](#)
  - LGBTQ+ focused
- ▶ **Availability**
  - JYNNEOS vaccine remains available through Strategic National Stockpile
  - Most of NH inventory expires 10/2024
- ▶ **Future supply**
  - Discussion at the Federal level for transitioning back to the commercial supply chain

# Mpox Vaccine Updates

- ▶ **Transition to routine vaccination**
  - ACIP will meet 3 times late summer / early fall 2023
  - June - Review clinical considerations for the use of JYNNEOS during mpox outbreaks
  
- ▶ **Continue to vaccinate those at highest risk**
  - NH guidance remains the same and can be found at;  
[Monkeypox Virus Outbreak, Update #4](#)
  
- ▶ **Public Health Partners Call**
  - <https://www.dhhs.nh.gov/programs-services/disease-prevention/infectious-disease-control/bidc-resources-healthcare-providers>

# RSV Vaccine Updates

# RSV Vaccine

- ▶ **May 3<sup>rd</sup>, 2023 – FDA approve first RSV vaccine**
  - Arexvy™ – GlaxoSmithKline Biologicals
  - Contains one antigen component (RSVpreF3)
  - Approved for use in adults age 60 and older
  - Clinical trial to expand to adults aged 50-59 with comorbidities is fully recruited with results anticipated later in 2023
  
- ▶ **May 31<sup>st</sup>, 2023 – FDA approves second RSV vaccine**
  - ABRYOVO™ – Pfizer
  - Contains two antigen components (RSVpreF A and RSVpreF B)
  - Approved for use in adults age 60 and older
  - Also granted priority review for the prevention of RSV in infants (birth to six months of age) by active immunization of pregnant individuals

# RSV Vaccine

## ▶ **Advisory Committee on Immunization Practices**

- Next meeting June 21<sup>st</sup> – June 23<sup>rd</sup>
- June 21<sup>st</sup> – Potential vote on recommendations for adults for both Pfizer and GSK formulations
- June 22<sup>nd</sup> – Potential vote on recommendations for Pfizer maternal use

## ▶ **SB 35**

- Signed by Gov. Sununu on 6/6/2023
- Amend RSA 318 to allow administration of RSV vaccine by pharmacists, pharmacy interns, and advanced practice pharmacy technicians

# RSV

## ► Other RSV News

- June 8<sup>th</sup> 2023 - FDA approved nirsevimab (Beyfortus)
- FDA's Antimicrobial Drugs Advisory Committee
- Sanofi/AstraZeneca joint venture
- Monoclonal antibody for the prevention of RSV
  - Neonates/infants born during or entering their first RSV season
  - Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
- Approved in EU fall 2022 and Canada in spring 2023




# RSV

## ► Not a vaccine?

- Recombinant, fully human, long acting monoclonal antibody
- Provides passive immunization by binding to a epitope site on the perfusion RSV F protein
- Inhibits a essential membrane fusion step in the viral entry process
- Directly neutralizes RSV and block cell to cell fusion

# RSV



AstraZeneca

# Other Vaccine News

# Other Vaccine News

## ▶ NH VFC List

- Two new formulations in the process to be added to the NH VFC list
  - PRIORIX (Measles, Mumps, Rubella Vaccine)
    - Available effective January 1<sup>st</sup>, 2023
  - Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine)
    - Available to order beginning April 1<sup>st</sup>, 2023

## ▶ Prevnar 20

- April 27<sup>th</sup>, 2023 – FDA granted approval for use in infants and children (6 week through 17 years of age)
- On the ACIP meeting agenda for June 22<sup>nd</sup>

# Resources

## ▶ CDC Vaccine Resources are available

- [JYNNEOS Vaccine Overview & Training](#)
  - Vaccination Schedule
  - Dosing Intervals
  - Patient Counseling

## ▶ Other Federal Resources

- [Vaccine Adverse Event Reporting System \(VAERS\)](#)
- [Vaccine Administration Errors and Deviations](#)

# Q&A

Thank you for your attention.

Feel free to contact me at:  
[Ryan.m.tannian@dhhs.nh.gov](mailto:Ryan.m.tannian@dhhs.nh.gov)